Pancreatic Cancer Research

ResearcherCentre National de la Recherche ScientifiqueActive in the last 2 years

Ilaria Cascone

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4903-8926; OpenAlex author ID A5063835507. Sources: OpenAlex.

Their work

Papers
12 (first author 0, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
25
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: 3 papers · 2022: 2 papers · 2023: none · 2024: 2 papers · 2025: 2 papers · 2026: 1 paper

Papers 12

  1. Paclitaxel-loaded nanostructured lipid carriers surface-functionalized with N6L for pancreatic cancer. Co-author DOI 10.1016/j.biopha.2026.119797↗
  2. The nucleolin antagonist N6L and paclitaxel combination treatment could be a new promising therapeutic strategy for pancreatic ductal adenocarcinoma therapy. Last author DOI 10.1016/j.ejphar.2025.177310↗
  3. Corrigendum to "The nucleolin antagonist N6L and paclitaxel combination treatment could be a new promising therapeutic strategy for pancreatic ductal adenocarc… Last author DOI 10.1016/j.ejphar.2025.177383↗
  4. Matrix stiffness regulates the protein profile of extracellular vesicles of pancreatic cancer cell lines. Last author DOI 10.1002/pmic.202400058↗
  5. TNFR2 blockade promotes antitumoral immune response in PDAC by targeting activated Treg and reducing T cell exhaustion. Co-author DOI 10.1136/jitc-2024-008898↗
  6. Nucleolin Therapeutic Targeting Decreases Pancreatic Cancer Immunosuppression. Last author DOI 10.3390/cancers14174265↗
  7. Correction: Ponzo et al. Nucleolin Therapeutic Targeting Decreases Pancreatic Cancer Immunosuppression. Cancers 2022, 14, 4265. Last author DOI 10.3390/cancers14246160↗
  8. Pharmacologic Normalization of Pancreatic Cancer-Associated Fibroblast Secretome Impairs Prometastatic Cross-Talk With Macrophages. Co-author DOI 10.1016/j.jcmgh.2021.01.008↗
  9. Nucleolin Targeting by N6L Inhibits Wnt/β-Catenin Pathway Activation in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/cancers13122986↗
  10. Nucleolin Aptamer N6L Reprograms the Translational Machinery and Acts Synergistically with mTORi to Inhibit Pancreatic Cancer Proliferation. Co-author DOI 10.3390/cancers13194957↗
  11. Fabrication of large pore mesoporous silica microspheres by salt-assisted spray-drying method for enhanced antibacterial activity and pancreatic cancer treatme… Co-author DOI 10.1016/j.ijpharm.2020.119930↗
  12. Nucleolin Targeting Impairs the Progression of Pancreatic Cancer and Promotes the Normalization of Tumor Vasculature. Last author DOI 10.1158/0008-5472.can-16-0300↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. José Laurent Cohen · 7 shared papers, 2021–2025 · strength 1.17
  2. Sabrina Belbekhouche · 4 shared papers, 2020–2026 · strength 0.90
  3. Benedetta Ferrara · 4 shared papers, 2020–2025 · strength 0.78
  4. Matteo Ponzo · 5 shared papers, 2021–2024 · strength 0.60
  5. Philippe Bouvet · 5 shared papers, 2016–2022 · strength 0.53
  6. Anaïs Debesset · 4 shared papers, 2021–2024 · strength 0.51
  7. Mounira Chalabi‐Dchar · 4 shared papers, 2021–2022 · strength 0.49
  8. Fabrice Raineri · 2 shared papers, 2025 · strength 0.47
  9. Fabio Raineri · 3 shared papers, 2021–2022 · strength 0.34
  10. Rémy Nicolle · 3 shared papers, 2021–2022 · strength 0.32
  11. Corinne Bousquet · 3 shared papers, 2021–2022 · strength 0.32
  12. Laura Larue · 1 shared paper, 2026 · strength 0.32
  13. Christophe Tournigand · 2 shared papers, 2022 · strength 0.23
  14. Jerome F. Cros · 2 shared papers, 2021 · strength 0.20
  15. Anne Couvelard Benveniste · 2 shared papers, 2016–2021 · strength 0.15
  16. Alfred P. Weber · 1 shared paper, 2020 · strength 0.11
  17. Cindy Neuzillet · 1 shared paper, 2021 · strength 0.09
  18. Yvan Martineau · 1 shared paper, 2021 · strength 0.09
  19. Jérôme Raffenne · 1 shared paper, 2021 · strength 0.09
  20. Stéphane Pyronnet · 1 shared paper, 2021 · strength 0.09
  21. Rémi Samain · 1 shared paper, 2021 · strength 0.09
  22. Richard Tomasini · 1 shared paper, 2021 · strength 0.09
  23. Jérémy Nigri · 1 shared paper, 2021 · strength 0.09
  24. Christine Jean · 1 shared paper, 2021 · strength 0.09
  25. Maud-Emmanuelle Gilles · 1 shared paper, 2016 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.